Synthace
Digital experiment platform for life sciences
- 21-100 employees
- B2B
- Biology
- Automation
- Shepherd's Bush, London, UK
Jump to section
Company mission
To help solve the most pressing problems facing scientists today and, in turn, humanity's future.
Our take
Synthace was founded in order to harness the power of biological innovation and benefit both the environment, and humanity. This is helping to revolutionise how biotechnology is used and developed, helping directly to contribute to more efficient and faster research into curing diseases and doing real social good.
The business is currently rapidly scaling, and is focusing on the software reliability of its platform, Synthace, to continue this growth. This software platform allows technicians to get more out of existing lab equipment, while lowering the entry bar for scientists to automate elements of their work.
The applications of this software are potentially massively wide-ranging, allowing scientists to design biological experiments, run simulations, translate instructions for automated and robotic lab technology, and visualise the resulting complex datasets. By combining the digital ecosystem with the physical experiment, Synthace is building the foundations for the Labs of the future.
With this approach, Synthace is helping to drive the 'fourth industrial revolution', developing systems offering scientists the tools to help find cures for diseases like cancer sooner. Having worked with clients including Oxford Biomedica, GSK, and Microsoft, it is well placed to continue growing and spreading its cloud-based SaaS product and grow its customer base
Kirsty
Company Specialist at Welcome to the Jungle
Benefits
- We trust and support our people to work in the ways that suit them best. This means flexibility about however, whenever, and wherever you need to get stuff done
- We take health and wellbeing seriously. At Synthace, you’ll find generous pension contributions (10%), solid health cover, volunteering days
- Great equity/share options, hybrid working, flexible hours, extra time off to detach from work with quarterly company-wide days off
- Employee support line
- Enhanced parental leave pay in UK and US
- 25 days holiday (excl. bank holidays) in the UK
- 20 days PTO (excl. bank holidays) in the US
- Cycle to work scheme
Funding (last 2 of 6 rounds)
Nov 2021
$35m
SERIES C
Dec 2018
$25.6m
SERIES B
Total funding: $76.2m
This company has top investors
Leadership
Markus Gershater
(Chief Science Officer)Having studied a PhD in Biochemistry at Durham, Markus worked at Novacta Biosystems as a Biotransformation Scientist, and Post-Doctoral Research Associate at UCL. In March 2011, he co-founded Synthace, where he has served as Chief Scientific Officer since.